Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. announced it will report its second quarter 2026 financial results on Thursday, July 30, 2026, before the market opens. Following the release, the company will host an audio webcast at 8:30 a.m. ET to discuss the results. Investors can access the financial results and live webcast through the Investor Relations section of Amneal's website.

Amneal Pharmaceuticals and Zambon announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for Hopledo® in Europe. Hopledo®, known as CREXONT® in the U.S., is a novel oral formulation for Parkinson's disease patients experiencing moderate to severe motor fluctuations. This recommendation, based on positive Phase 3 trial data, paves the way for a new treatment option for over one million Parkinson's patients in the EU, with a phased launch expected to begin in October 2026.

Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study for CREXONT (carbidopa and levodopa) extended-release capsules. The study, involving 214 patients, demonstrated clinically meaningful benefits, including substantial increases in "Good On" time, reductions in "Off" time, and improved motor function, regardless of prior treatment. Patients switching from RYTARY® nearly doubled their continuous "Good On" intervals. The safety profile was consistent with prior therapy, and the company recently received an FDA labeling update for an additional administration option.

Amneal Pharmaceuticals announced that Chirag Patel, Co-Chief Executive and President, will participate and present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The company presentation is scheduled for Tuesday, June 9, 2026, at 8:40 AM EDT, and a live webcast will be available for interested parties.

Amneal Pharmaceuticals reported a significant increase in its first-quarter 2026 financial results, with net income attributable to the company soaring to $62.26 million and diluted EPS reaching $0.19. Net revenue also saw a modest increase to $722.52 million. The company recognized a $6.9 million gain from a change in its Pfizer collaboration agreement and successfully repriced its Term Loan, reducing interest rate margins. However, net cash used in operating activities was $26.74 million for the quarter.

Amneal Pharmaceuticals, Inc. announced strong first quarter 2026 results, with net revenue reaching $723 million, a 4% increase year-over-year. GAAP net income surged by 411% to $62 million, and diluted income per share rose by 375% to $0.19. The company also reported a 19% increase in Adjusted EBITDA to $202 million and a 29% rise in Adjusted Diluted EPS to $0.27, affirming its previously announced increased full-year 2026 guidance.

Amneal Pharmaceuticals, Inc. has entered into an agreement to acquire 100% of Kashiv BioSciences, LLC. The acquisition involves an upfront payment of $375 million in cash and the issuance of 28,942,108 shares of Amneal's Class A common stock. Additionally, Kashiv's equityholders are eligible to receive up to $350 million in contingent payments based on regulatory milestones for six product candidates, plus potential royalty payments for 12 years post-closing. This strategic move aims to expand Amneal's portfolio and capabilities.

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for an upfront consideration of $750 million ($375M cash, $375M equity) plus up to $350 million in potential milestone payments. This acquisition aims to establish a fully integrated global biosimilars platform, positioning Amneal to capitalize on a projected $300 billion+ global biologics loss-of-exclusivity wave. The company also reported continued growth in preliminary Q1 results and raised its full-year 2026 guidance, expecting the transaction to accelerate growth and diversification.

Amneal Pharmaceuticals announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, both FDA-approved in 2025. These are the company's first metered-dose inhalation (MDI) products, marking its entry into the complex inhalation category. The albuterol product is a generic equivalent of PROAIR® HFA, with annual sales of approximately $1.5 billion, while the beclomethasone product is a generic equivalent of QVAR® Inhalation Aerosol, with annual sales of about $321 million. This strategic move expands Amneal's respiratory platform and addresses patient access gaps.